Results 131 to 140 of about 242,018 (254)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia

Turkish Journal of Hematology, 2021
Keisuke Kidoguchi, Yasushi Kubota, Yuki Nishimura, Haruna Sano, Shinya Kimura   +4 more
doaj   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Induction of IL‐9‐producing CD8+ T cells by ascochlorin derivatives

British Journal of Pharmacology, Volume 183, Issue 11, Page 3015-3031, June 2026.
A newly synthesised ascochlorin derivative, N184, induces small amounts of IL‐9‐producing CD8+ T cells. N184 improved the survival of CD8+ T cells and enhanced their antitumour activity, partially in an IL‐9‐dependent manner. The antitumour effect was completely dependent on IFNγ secretion rather than the cytotoxic activity of CD8+ T cells.
Natsumi Imano, Mikako Nishida, Miho Tokumasu, Weiyang Zhao, Nahoko Yamashita, Heiichiro Udono   +5 more
wiley   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Upregulation of CD1d and ULBP3 on B cells from healthy donors and chronic lymphocytic leukaemia patients does not prime them for killing by γδ T cells. [PDF]

PLoS One
David J, Walsh A, Seow KS, Walsh E, Elekes S, Upadhyay R, Taher NAB, Al Siyabi S, Melo AM, Waldron C, Vandenberghe E, McElligott AM, Doherty DG.   +12 more
europepmc   +1 more source

CLL-IPI in MBL and CLL [PDF]

Blood, 2021
openaire   +1 more source

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, Volume 116, Issue 6, Page 873-882, June 2026.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source

Hypertension affects survival and treatment in chronic lymphocytic leukemia. [PDF]

Blood Adv
Vainer N, Brieghel C, Rostgaard K, Davíðsson ÓB, Dietz JB, Frederiksen CM, da Cunha-Bang C, Hjalgrim H, Niemann CU, Rotbain EC.   +9 more
europepmc   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, Volume 116, Issue 6, Page 759-770, June 2026.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

A 3D lymph node model for chronic lymphocytic leukaemia recapitulates microenvironmental features and drug response in vitro. [PDF]

Dis Model Mech
Belloni D, Barozzi D, Milani G, Barbaglio F, Puthukkunnath AR, Ranghetti P, Perotta E, Musco T, Sampietro M, Ponzoni M, Scarfò L, Ghia P, Scielzo C.   +12 more
europepmc   +1 more source